Will MetLife Egypt and AXA Egypt cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Beovu is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDA?

The EDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Egyptian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Egyptian Medical Syndicate and the EDA verifies the active license; the EDA application records both the prescribing physician and the dispensing facility.

Can I receive Beovu at home?

The dispensing facility must be Egyptian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 1,900 to 2,200 per dose. Delivered quote within 24h.Get my quote

Beovu access in Egypt: the EDA named-patient pathway

How patients in the Arab Republic of Egypt legally obtain Beovu (brolucizumab-dbll) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Egypt access Beovu (brolucizumab-dbll) for neovascular (wet) age-related macular degeneration and diabetic macular edema through the EDA named-patient pathway, an Egyptian Drug Authority-administered mechanism that allows an Egyptian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in EGP.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Beovu reaches patients in Egypt

Beovu (brolucizumab-dbll, a humanised single-chain antibody fragment that binds VEGF-A isoforms from Novartis) received US FDA approval in October 2019 for neovascular (wet) age-related macular degeneration, with a 2022 extension to diabetic macular edema, administered as a 6 mg intravitreal injection on a three monthly loading dose followed by a maintenance schedule of every 8 to 12 weeks per the FDA label at accessdata.fda.gov/scripts/cder/daf. The FDA label and the EMA Summary of Product Characteristics carry a warning for retinal vasculitis and retinal vascular occlusion identified through post-marketing safety review per the EMA EPAR at ema.europa.eu/medicines/human/EPAR/beovu, which the prescribing retinal specialist incorporates into the patient-counselling and monitoring plan. The Egyptian Drug Authority registered-drug database at eservices.edaegypt.gov.eg includes brolucizumab under Novartis Egypt registration; presentation availability across the governorate-pharmacy network can be intermittent. Where the locally stocked presentation does not match the prescribed regimen or the patient was previously stabilised on the US-sourced product, Egyptian patients use the Personal Importation of Unregistered Medicines pathway operated by the EDA Central Administration for Pharmaceutical Affairs under Pharmacy Practice Law No. 127 of 1955, Health Minister Decree No. 296 of 2009, and the post-2019 EDA framework at edaegypt.gov.eg. The treating Egyptian-licensed vitreoretinal specialist issues a stamped medical report documenting the wet AMD or DME diagnosis with optical coherence tomography and fluorescein angiography findings, the prior anti-VEGF exposure (typically ranibizumab, aflibercept, or off-label bevacizumab), the response or sub-response history, and the planned Beovu schedule referencing the HAWK and HARRIER phase 3 trials per the FDA medical review. EDA does not publish a fixed processing-time SLA; reporting indicates one to three weeks when documentation is complete, longer for cold-chain biologic verification.

Where Beovu is dispensed in Egypt

Beovu is administered as an intravitreal injection in a sterile-procedure setting by a vitreoretinal specialist with prior and post-procedure OCT imaging and dilated fundus examination. The Egyptian tertiary and dedicated ophthalmology centres equipped for intravitreal anti-VEGF therapy with named-patient specialty-drug handling include the Research Institute of Ophthalmology in Giza (Cairo), the national public ophthalmology reference centre with retina service at rio.gov.eg; Magrabi Eye Hospitals in Cairo, Alexandria, and Sharm El-Sheikh, the regional private eye-hospital chain with vitreoretinal service at magrabi.com.eg; Cairo University Hospitals (Kasr Al-Ainy) Department of Ophthalmology at kasralainy.edu.eg; Ain Shams University Hospitals Department of Ophthalmology in Cairo; and Alexandria University Hospitals Memorial Institute of Ophthalmology Research at alexmed.edu.eg. Dar Al Oyoun Hospital and Egypt Air Eye Hospital in Cairo handle private vitreoretinal cases with named-patient anti-VEGF imports. Magrabi Eye Hospitals and the Research Institute of Ophthalmology are the most frequent dispensing nodes for intravitreal specialty therapy because of injection-room infrastructure and cold-chain handling capacity.

What Beovu costs in Egypt

The US wholesale acquisition cost for Beovu is reported by Novartis at approximately USD 1,850 per 6 mg pre-filled syringe single-dose unit per the FDA Drugs@FDA channel at accessdata.fda.gov/scripts/cder/daf, with annual drug-only spend in the range of USD 11,000 to USD 16,000 depending on whether the patient maintains every-8-week or every-12-week dosing after the three-dose load. Price snapshot: 2026-06-01. The local Egyptian retail price for brolucizumab where commercially stocked is set by the EDA Pricing Committee under EDA pricing policy; the EDA pricing reference for Beovu has historically been disclosed by Egyptian pharmacy networks, though no current EDA-published EGP MRP for Beovu is observed on the public pricing channel at edaegypt.gov.eg as of 2026-06-01; do not estimate. The Central Bank of Egypt USD reference rate has been volatile through 2024 to 2026. Cost layers beyond the drug include refrigerated 2 to 8 degrees Celsius cold-chain logistics (Beovu requires continuous temperature logging through the lane), the EDA permit and customs duties, the dispensing facility intravitreal injection fees and OCT/imaging fees, and the Reserve Meds concierge fee itemised separately on every firm quote. Local commercial stock when available is materially cheaper than US-sourced personal import.

Funding and access barriers for Beovu in Egypt

Anti-VEGF therapy funding in Egypt is comparatively well-developed because wet AMD and diabetic macular edema are recognised high-burden conditions. The Universal Health Insurance Authority (UHIA) at uhia.gov.eg covers intravitreal anti-VEGF therapy in implementation governorates for insured citizens under the joint formulary with the Unified Procurement Authority; ranibizumab biosimilars and aflibercept are typically the standard reimbursed first-line options, with brolucizumab reimbursement assessed case by case per HTA process. The Health Insurance Organisation (HIO) covers intravitreal anti-VEGF therapy for enrolled employees and pensioners in pre-UHI governorates. Major private insurers (MetLife Egypt, AXA Egypt, Allianz Egypt, Misr Insurance, GlobeMed Egypt as TPA, Med Net) cover intravitreal anti-VEGF therapy with prior authorisation and step therapy from less expensive first-line options before Beovu. Out-of-pocket spending dominates per World Bank data at data.worldbank.org, and the practical out-of-pocket cost for a wet AMD patient on private payer step-therapy denial is the binding access constraint. The post-marketing safety signal for retinal vasculitis and retinal vascular occlusion has shaped Egyptian retinal-specialist prescribing patterns and informs the Beovu eligibility narrative in clinical-justification letters, with prior anti-VEGF inadequate response and adequate OCT documentation as the typical anchors.

Recent regulatory and access news for Beovu

The FDA reaffirmed the Beovu post-marketing safety language for retinal vasculitis and retinal vascular occlusion through ongoing risk-evaluation activity per the FDA Drugs@FDA listing at accessdata.fda.gov/scripts/cder/daf. The American Academy of Ophthalmology and the European Society of Retina Specialists EURETINA at euretina.org published updated clinical-practice guidance on anti-VEGF selection through 2024 and 2025 incorporating the brolucizumab safety profile alongside efficacy data, providing the clinical-evidence anchor Egyptian retinal specialists cite in EDA personal-import justifications. UHIA and the Unified Procurement Authority have continued the phased UHI rollout per UHIA bulletins at uhia.gov.eg; intravitreal anti-VEGF reimbursement applies differently in implementation versus non-implementation governorates. No drug-specific EDA bulletin for Beovu or brolucizumab over the last 12 months has been observed as of 2026-06-01.

Where Reserve Meds fits in Beovu cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDA, and we do not replace your dispensing pharmacy. For Beovu specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Egypt, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Beovu case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Beovu is administered by intravitreal injection in a sterile clinic setting; named-patient files in Egypt document the baseline OCT and FAF imaging, the FDA-labelled dosing schedule for the specific indication (wet AMD, DME, RVO, or DR), and the retinal specialist's intravitreal injection volume. Cold-chain (2 to 8 degrees Celsius) handling is required through the dispensing pharmacy with continuous temperature logging; the dispensing pharmacy releases the medicine for same-session injection at the clinic rather than for outpatient home storage.

Next step

If your Egyptian physician has prescribed Beovu and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Beovu case Or message us on WhatsApp